Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that its Decipher Prostate Genomic Classifier is now the only gene expression test included in version 1 of the 2025 NCCN® Clinical Practice Guidelines in Oncology (NCCN Guidelines®). It is featured in the updated “Advanced Tools” table under the Principles of Risk Stratification and Biomarkers section (PROS-H).
“The Decipher Prostate test’s performance and clinical utility have been demonstrated in numerous peer-reviewed studies, including analyses from multiple Phase 3 clinical trials, making it the most validated test for prostate cancer,” said Phil Febbo, M.D., Veracyte’s Chief Scientific Officer and Chief Medical Officer. “Its unique status in the NCCN guidelines reflects the evidence generated through our dedication to research and collaborations with leading prostate cancer experts worldwide.”
The Decipher Prostate test is a 22-gene signature derived from whole-transcriptome analysis that helps clinicians assess the risk of a prostate tumor progressing to metastatic disease. This valuable information enables clinicians to recommend either less-intensive or more aggressive treatments depending on the patient’s risk level.
“The Decipher Prostate test is already the most widely used molecular test in prostate cancer. Its inclusion in the updated NCCN guidelines will help expand access to even more patients,” said Marc Stapley, Veracyte’s Chief Executive Officer. “This milestone underscores the strength of our Veracyte Diagnostics Platform, which allows us to develop high-performing, well-validated tests like Decipher Prostate that are transforming cancer care.”
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test developed using RNA whole-transcriptome analysis and machine learning. It helps inform treatment decisions for prostate cancer patients by providing an accurate risk of metastasis under standard treatment. With this information, physicians can better personalize care by recommending less-intensive treatment for lower-risk patients or more intensive treatment for those at higher risk of metastasis. The test has been validated in numerous published studies involving over 100,000 patients and is the only gene expression test included in the latest NCCN® Guidelines for prostate cancer.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company focused on transforming cancer care. The company provides clinicians with critical insights to guide and reassure patients during pivotal moments in their cancer diagnosis and treatment journey. Through its Veracyte Diagnostics Platform, Veracyte delivers high-performing cancer tests driven by extensive genomic and clinical data, advanced bioinformatics, AI capabilities, and robust evidence-generation. This approach ensures strong reimbursement, guideline inclusion, and continuous innovation in cancer care.
